BACKGROUND
Epilepsy is the commonest serious neurological condition. In the UK between 1 in 140 and 1 in 200 people (at least 300 000 people) are currently being treated for epilepsy. People with epilepsy have a 2-3 times higher risk of premature death than the general population. Every year in the UK about 1000 people die because of epilepsy, and most of these deaths are associated with seizures. Sudden unexpected death in epilepsy or SUDEP is estimated to account for about 500 deaths each year in the UK 1 .
Epidemiological studies suggest that between 70 and 80% of people developing epilepsy will go into remission. The remaining patients continue to have seizures and are refractory to treatment with the currently available therapies 2 . It is possible that a number of factors, including genetics, which are as yet undetermined, contribute to the development of intractable seizures. Nutrition is likely to be one of these factors and, in particular, deficiency in omega-3 fatty acids might be an important factor. Nutritional studies suggest that the Western diet is deficient in omega-3 fatty acids 3 , which is an essential nutrient. Hence people with epilepsy in the UK, like those in the general population, are likely to be deficient in omega-3 fatty acids. Omega-3 fatty acids have important roles in determining the structural and functional properties of neuronal membranes, affecting membrane functions such as electrical signalling, receptor sensitivity and neurotransmitter release.
SEIZURE ASSOCIATED CARDIAC ARRHYTHMIAS AND SUDEP
It is recognised that seizures can be associated with heart rate changes and ECG abnormalities. In one study of 281 seizures in 81 patients, there was an increase in heart rate of at least 10 bpm in 73% of seizures (93% of patients). ECG abnormalities were found in 26% of seizures (44% of patients), with potentially serious abnormalities (asystole, sinus pause, ST-segment elevation/depression, T-wave inversion) in 29 seizures (11 patients) . This study also showed an increased risk of ECG abnormalities with increased seizure duration 4 .
SUDEP in epilepsy is defined as the sudden, unexpected, witnessed or unwitnessed, non-traumatic and non-drowning death in patients with epilepsy, with or without evidence for a seizure, and excluding documented status epilepticus, in which post-mortem examination does not reveal a toxicological or anatomical cause for death. In one case controlled study, the following were found to be risk factors for SUDEP: greater number of seizures, greater number of AEDs, early onset of epilepsy and frequent changes in AED dosages 5 . The data suggest that SUDEP is a seizure-related event.
The cause of SUDEP has not been fully elucidated, but the death is often thought to be a seizure-related event. Cardiac tachyarrhythmias, bradyarrhythmias and sinus arrest, and central hypoventilation which may result from the release of endogenous opioids have all been suggested as possible mechanisms 6 . It is possible that the cause is multifactorial or is different in different people. The circumstances of death suggest to us and other authors that cardiac arrhythmias are likely to be one of the more important causes of SUDEP 7 .
ANTI-SEIZURE EFFECTS OF OMEGA-3 FATTY ACIDS
Studies have shown that the omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) applied extracellularly raise the stimulatory thresholds of CA1 neurones in hippocampal slices 8 . Infusion of EPA and DHA were equipotent in raising seizure thresholds in a cortical stimulation seizure model in the male Wistar rat 9 . Prolonged oral administration of alpha-linolenic acid (an omega-3 fatty acid) and linoleic acid in a 1:4 mixture protected rats from having seizures in four different epilepsy models 10 .
Other pharmacological studies show that prostaglandin E2 and other pro-inflammatory mediators are elevated in animal models of epilepsy 11, 12 . The enzymes, phospholipase A2 (PLA2) that releases arachidonic acid from membrane phospholipids, and oxidoreductase cyclooxygenase-2 (COX2) that converts arachidonic acid to pro-inflammatory mediators, are activated or induced by seizures 13, 14 . Antiinflammatory steroids reduce pro-inflammatory mediators by inhibiting the expression of COX2 and PLA2 enzymes. ACTH and prednisone are known to reduce localised and generalised seizures, and are used in the treatment of a number of intractable epilepsy syndromes. Additionally, increasing anti-inflammatory mediators appear to have anti-convulsant effects 12 In an open study, five patients with intractable seizures were given a special spread containing 2.3 g of DHA and 0.9 g of EPA for 6 months. Three patients became seizure free and the other two had a greater than 50% seizure reduction at the end of the trial 17 .
OMEGA-3 FATTY ACIDS REDUCE CARDIAC ARRHYTHMIAS AND SUDDEN CARDIAC DEATHS
In animal feeding studies, omega-3 fatty acids prevented fatal ischaemia-induced cardiac arrhythmias. Omega-3 fatty acids also prevented such arrhythmias in surgically prepared, conscious, exercising dogs. Omega-3 fatty acids have been shown in rat cardiac myocyte preparations to prevent or terminate tachyarrhythmias induced by various arrhythmogenic toxins. The action of omega-3 fatty acids is to stabilise cardiac myocytes in the heart, increasing by 50% the stimulus needed to elicit an action potential, and prolonging the relative refractory time by approximately 150% 18 .
The GISSI-Prevenzione trial of 850-882 mg daily of EPA and DHA in 11 324 patients following a first myocardial infarction, showed a significant reduction in cardiovascular deaths (30% reduction) and sudden deaths (45% reduction) compared with controls 19 . Most patients were already on a risk reduction regimen comprising aspirin, beta-blockers, angiotensin converting enzyme inhibitors and/or lipid lowering statins. Time-course analysis of the data showed that the survival curves for patients receiving EPA and DHA began to diverge from those of controls early after randomisation and that total mortality was significantly lower after 3 months. Increased survival was predominantly due to a reduction in the risk of sudden death. The data strongly support an anti-arrhythmic effect of EPA and DHA 20 . A study involving 20 551 healthy US physicians demonstrated that those who consumed fish at least weekly, compared with those taking it less than monthly, had a lower risk of sudden cardiac deaths. Sudden cardiac deaths were mainly attributed to cardiac arrhythmias 21 .
HYPOTHESIS
In a proportion of patients seizures are known to be associated with the occurrence of cardiac arrhythmias, some of which are potentially serious. The circumstances of SUDEP deaths and the lack of post-mortem findings suggest that cardiac arrhythmias may be an important cause or factor. Higher intake of EPA and DHA either in the diet or through supplementation has been shown to reduce sudden cardiac deaths in healthy subjects and in survivors of myocardial infarction. We postulate that EPA and DHA supplementation in patients with intractable seizures will reduce cardiac arrhythmias associated with seizures and hence the incidence of SUDEP in the treated population. This would be in keeping with anecdotal comments from our Mediterranean colleagues that SUDEP occurs rarely in their patient population. The Mediterranean diet is known to contain a higher proportion of omega-3 fatty acids than the UK diet. As SUDEP is associated with seizures, reducing total seizure frequency should further contribute to reducing the incidence of SUDEP. EPA and DHA supplementation appears to have anti-epileptic effects in animal studies and a preliminary clinical observation.
TESTING THE HYPOTHESIS
The methodology for testing the anti-epileptic properties of therapies is well established and trials are underway to confirm the anti-epileptic effects of EPA and DHA. The optimal dose of EPA and DHA has yet to be established. In the one clinical trial reported, the patients received 2.3 g of DHA and 0.9 g of EPA in a bread spread 17 . Review of omega-3 fatty acid supplementation studies suggest that frequently the higher doses used in trials did not show benefit. In particular, in a dose ranging study in schizophrenia, 2 g/day of ethyl-EPA gave the best response whilst 4 g/day was considerably less effective, and in a study of depression 1 g/day of ethyl-EPA was more effective than 2 and 4 g/day 22 . In the GISSI-Prevenzione trial patients received 850-882 mg of EPA and DHA in a ratio of EPA:DHA of 1:2 19 . These data may suggest that the optimal total daily dose of EPA and DHA for people with epilepsy is likely to be between 850 and 2000 mg. In one of the on-going trials to confirm the anti-epileptic effects of EPA and DHA, a total daily dose of 1700 mg (EPA:DHA of 3:2) is administered as six capsules.
Patients with epilepsy who have been identified through Holter or Reveal implantable loop recorder monitoring to have cardiac arrhythmias can be studied in controlled trials to examine the effect of EPA and DHA on the frequency of seizure-related arrhythmias. The definitive way to test this hypothesis is to randomise large groups of patients with intractable epilepsy to receive EPA and DHA supplementation. In the novel anti-epileptic drug trial programmes in patients with intractable seizures, SUDEP rates of 2.8-3.9 per 1000 person years are observed 23 . If EPA and DHA supplementation were to reduce this rate from 4 to 1 per 1000 person years, then 6000 patients treated for a year per treatment arm would be required to detect this difference with 90% power at the 5% level of significance. This is using the log rank test in survival analysis that treats deaths from other causes as censored observations.
The above hypothesis supports the exhortation 'Let your food be your medicine' and reflects the increasing attention that medicine is focusing on nutrition in the overall management of health.
